| 產品編號 | bs-0729R |
| 英文名稱 | Rabbit Anti-KCNMA1/BK channel antibody |
| 中文名稱 | 鈣激活鉀通道蛋白 α 1抗體 |
| 別 名 | Maxi Potassium channel alpha; bA205K10.1; BK channel; BKCa channels; BKCA alpha; BKCA alpha subunit; BKTM; Calcium activated potassium channel subfamily M subunit alpha 1; Calcium activated potassium channel subunit alpha 1; DKFZp686K1437; Drosophila slowpoke like; hSlo; K(VCA)alpha; KCa1.1; KCNMA 1; KCNMA; KCNMA1; Large conductance calcium activated potassium channel subfamily M alpha member 1; Maxi K; Maxi K channel; MaxiK; Potassium large conductance calcium activated channel subfamily M alpha member 1; SAKCA; Slo 1; SLO alpha; SLO; Slo homolog; Slo1; Slowpoke homolog; Stretch activated Kca channel; KCMA1_HUMAN. |
 |
Specific References (1) | bs-0729R has been referenced in 1 publications.
[IF=3.23] Sudduth, Tiffany L., et al. "Time-course of glial changes in the hyperhomocysteinemia model of vascular cognitive impairment and dementia (VCID)." Neuroscience (2016). WB ; Mouse.
|
| 研究領域 | 神經生物學 信號轉導 通道蛋白 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Rat (predicted: Human,Mouse,Rabbit,Pig,Sheep,Cow,Dog) |
| 產品應用 | IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 137kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human BK channel: 1131-1236/1236 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
MaxiK channels are large conductance, voltage and calcium-sensitive potassium channels which are fundamental to the control of smooth muscle tone and neuronal excitability. MaxiK channels can be formed by 2 subunits: the pore-forming alpha subunit, which is the product of this gene, and the modulatory beta subunit. Intracellular calcium regulates the physical association between the alpha and beta subunits. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]. Function: Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key role in controlling excitability in a number of systems, such as regulation of the contraction of smooth muscle, the tuning of hair cells in the cochlea, regulation of transmitter release, and innate immunity. In smooth muscles, its activation by high level of Ca(2+), caused by ryanodine receptors in the sarcoplasmic reticulum, regulates the membrane potential. In cochlea cells, its number and kinetic properties partly determine the characteristic frequency of each hair cell and thereby helps to establish a tonotopic map. Kinetics of KCNMA1 channels are determined by alternative splicing, phosphorylation status and its combination with modulating beta subunits. Highly sensitive to both iberiotoxin (IbTx) and charybdotoxin (CTX). Subunit: Homotetramer. Subcellular Location: Membrane; Multi-pass membrane protein. Tissue Specificity: Widely expressed. Except in myocytes, it is almost ubiquitously expressed. Post-translational modifications: Phosphorylated (Probable). Phosphorylation by kinases such as PKA and/or PKG. In smooth muscles, phosphorylation affects its activity. DISEASE: Defects in KCNMA1 are the cause of generalized epilepsy and paroxysmal dyskinesia (GEPD) [MIM:609446]. Epilepsy is one of the most common and debilitating neurological disorders. Paroxysmal dyskinesias are neurological disorders characterized by sudden, unpredictable, disabling attacks of involuntary movement often requiring life-long treatment. The coexistence of epilepsy and paroxysmal dyskinesia in the same individual or family is an increasingly recognized phenomenon. Patients manifest absence seizures, generalized tonic-clonic seizures, paroxysmal nonkinesigenic dyskinesia, involuntary dystonic or choreiform movements. Onset is usually in childhood and patients may have seizures only, dyskinesia only, or both. Similarity: Belongs to the potassium channel family. Calcium-activated (TC 1.A.1.3) subfamily. KCa1.1/KCNMA1 sub-subfamily. Contains 1 RCK N-terminal domain. SWISS: Q12791 Gene ID: 3778 Database links: Entrez Gene: 3778 Human Entrez Gene: 16531 Mouse Omim: 600150 Human SwissProt: Q12791 Human SwissProt: Q08460 Mouse Unigene: 144795 Human Unigene: 343607 Mouse Unigene: 486347 Mouse Unigene: 30616 Rat 通道蛋白（Channel Protein） 該抗體主要用于細胞膜通道的研究。 |
| 產品圖片 |
Tissue/cell: rat stomach tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-BK channel/Maxi Potassium channel alpha Polyclonal Antibody, Unconjugated(bs-0729R) 1:100, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
